TB-500
Synthetic fragment of Thymosin Beta-4
What It Is
A synthetic peptide based on a fragment of Thymosin Beta-4, a protein naturally involved in cell structure and movement (actin regulation), studied mainly in the context of tissue repair.
Proposed Mechanism
Proposed to promote cell migration and blood vessel formation relevant to wound/tissue healing, based primarily on the parent protein's known biology and animal-model research on the fragment itself.
Areas Researchers Are Investigating
- Tissue and wound repair in animal models
- Cardiac tissue research (animal models)
- Sports-recovery contexts, driven largely by anecdotal/community interest rather than a deep human clinical evidence base
Human Evidence
Very limited. No substantial base of large controlled human clinical trials exists in the public literature.
Animal / Preclinical Evidence
The primary evidence base — rodent and other animal-model studies of tissue repair and wound healing.
Current FDA / Regulatory Status
Not FDA-approved for any human use. Frequently sold as a "research chemical," which does not make it lawful for human consumption. It is also a prohibited substance under World Anti-Doping Agency (WADA) rules — verify current WADA list status before publishing, as prohibited-substance lists are updated periodically.
Known Safety Information
No adequate human safety data exists at the scale needed to characterize a real safety profile. This absence of data is itself the key safety-relevant fact.
Limitations of Evidence
Almost entirely animal-model or anecdotal; no adequate controlled human trials to cite.